Multi-target kinase-IN-10

C57BL/6 (10 per group, MPTP-induced subacute model)^[1]

7.5 mg/kg; 15 mg/kg; 37.5 mg/kg

i.g.; daily

Significantly reduced motor deficits across all behavioral tests on days 1, 3, 7, and 14 at 37.5 mg/kg compared to the model group.
Showed significant improvements in most behavioral measures by day 7 at 15 mg/kg compared to the model group.
Showed a decreasing trend in motor deficits by day 3 and significant improvements by day 7 at 7.5 mg/kg compared to the model group.
Increased striatal dopamine levels by 60.5% at 37.5 mg/kg compared to the model group.
Reduced striatal malondialdehyde (MDA) content by 53.6% at 37.5 mg/kg compared to the model group.
Inhibited striatal TNF-α release by 67.1% and IL-6 release by 72.7% at 37.5 mg/kg relative to the model group.
Moderately restored dopamine levels, inhibited TNF-α release by 48.9%, and IL-6 release by 62.1% at 15 mg/kg compared to the model group.
Showed moderate dopamine recovery, inhibited TNF-α release by 24.2%, and IL-6 release by 45.8% at 7.5 mg/kg compared to the model group.
Significantly increased tyrosine hydroxylase (TH)-positive cell count in the substantia nigra pars compacta and enhanced TH-immunoreactive fiber density in the striatum at 37.5 mg/kg compared to the model group.